白术内酯Ⅰ在胃癌细胞中抑制输出蛋白T的作用和机制

doi:10.3969/j.issn.1006-5725.2024.14.005

Abstract

Abstract:

Objective This study aimed to investigate the role and mechanism of atractylenolide I in inhibiting XPOT proliferation and invasion in gastric cancer cells. Methods This study included exploration of XPOT expression in gastric cancer tissues， analysis of gene expression data from GC patients in TCGA and GEO databases， as well as various cellular assays to detect the ability of cancer cells to proliferate， migrate， and invade. Protein expression levels of XPOT， SKP2， CyclinA， and P27 mRNA were also detected by qPCR and Western Blot. Results Analysis confirmed that XPOT was highly expressed in gastric cancer tissues， indicating a poor prognosis. In vitro studies revealed that AT-1 inhibits the proliferation and invasion ability of GC cells； XPOT down-regulation also inhibits these abilities. Furthermore， AT-1 down-regulates the expression of XPOT which then regulates SKP2， P27， and CyclinA - ultimately inhibiting the proliferation and invasion of gastric cancer cells through the regulation of the XPOT pathway. Conclusion The overexpression of XPOT in gastric cancer tissues can indicate a poor prognosis. Atractylenolide I down-regulates the XPOT-regulated ubiquitination-proteasome pathway to inhibit proliferation and invasion of gastric cancer cells.

Key words: atractylodes macrocephala lactone I, gastric cancer, XPOT, ubiquitination proteasome pathway

CLC Number:

R735.2

Yi ZHANG,Fangqi MA,Siyuan WEI,Xuejun. LI. Role and mechanism of XPOT inhibition by atractylenolide I in gastric cancer cells[J]. The Journal of Practical Medicine, 2024, 40(14): 1928-1934.

Figures/Tables 5

References 26

1	NORWOOD D A， MONTALVAN-SANCHEZ E， DOMINGUEZ R L， et al. Gastric Cancer： Emerging Trends in Prevention， Diagnosis， and Treatment ［J］. Gastroenterol Clin North Am， 2022， 51（3）： 501-518. doi:10.1016/j.gtc.2022.05.001 doi: 10.1016/j.gtc.2022.05.001
2	LORDICK F， CARNEIRO F， CASCINU S， et al. Gastric cancer： ESMO Clinical Practice Guideline for diagnosis， treatment and follow-up ［J］. Ann Oncol， 2022， 33（10）： 1005-1020. doi:10.1016/j.annonc.2022.07.004 doi: 10.1016/j.annonc.2022.07.004
3	THRIFT A P， EL-SERAG H B. Burden of Gastric Cancer ［J］. Clin Gastroenterol Hepatol， 2020， 18（3）： 534-542. doi:10.1016/j.cgh.2019.07.045 doi: 10.1016/j.cgh.2019.07.045
4	LI K， ZHANG A， LI X， et al. Advances in clinical immunotherapy for gastric cancer ［J］. Biochim Biophys Acta Rev Cancer， 2021， 1876（2）： 188615. doi:10.1016/j.bbcan.2021.188615 doi: 10.1016/j.bbcan.2021.188615
5	LI G Z， DOHERTY G M， WANG J. Surgical Management of Gastric Cancer： A Review ［J］. JAMA Surg， 2022， 157（5）： 446-454. doi:10.1001/jamasurg.2022.0182 doi: 10.1001/jamasurg.2022.0182
6	吴珍珍，刘志宏，孙丽. PTEN诱导激酶1在预测胃癌患者预后及化疗疗效中的作用［J］. 实用医学杂志， 2021，37（10）：1272-1278. doi:10.3969/j.issn.1006-5725.2021.10.008 doi: 10.3969/j.issn.1006-5725.2021.10.008
7	宋早智，王庆康，孙家和，等. DOT1L在胃癌组织中的表达及其与预后的相关性［J］. 实用医学杂志， 2019，35（22）：3498-3502. doi:10.3969/j.issn.1006-5725.2019.22.015 doi: 10.3969/j.issn.1006-5725.2019.22.015
8	郭晨旭，刘静波，谢强，等. 白术内酯Ⅰ通过调低Cyclin D1/CDK4抑制胃癌细胞SGC-7901的增殖及机制［J］. 蚌埠医学院学报， 2020，45（4）：456-460. doi:10.13898/j.cnki.issn.1000-2200.2020.04.009 doi: 10.13898/j.cnki.issn.1000-2200.2020.04.009
9	DENG M， CHEN H， LONG J， et al. Atractylenolides （I， II， and III）： a review of their pharmacology and pharmacokinetics ［J］. Arch Pharm Res， 2021， 44（7）： 633-654. doi:10.1007/s12272-021-01342-6 doi: 10.1007/s12272-021-01342-6
10	BAILLY C. Atractylenolides， essential components of Atractylodes-based traditional herbal medicines： Antioxidant， anti-inflammatory and anticancer properties ［J］. Eur J Pharmacol， 2021， 891： 173735. doi:10.1016/j.ejphar.2020.173735 doi: 10.1016/j.ejphar.2020.173735
11	MA L， MAO R， SHEN K， et al. Atractylenolide I-mediated Notch pathway inhibition attenuates gastric cancer stem cell traits ［J］. Biochem Biophys Res Commun， 2014， 450（1）： 353-359. doi:10.1016/j.bbrc.2014.05.110 doi: 10.1016/j.bbrc.2014.05.110
12	LI Y， WANG Y， LIU Z， et al. Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells ［J］. Front Pharmacol， 2020， 11： 273. doi:10.3389/fphar.2020.00273 doi: 10.3389/fphar.2020.00273
13	LONG F， LIN H， ZHANG X， et al. Atractylenolide-I Suppresses Tumorigenesis of Breast Cancer by Inhibiting Toll-Like Receptor 4-Mediated Nuclear Factor-κB Signaling Pathway ［J］. Front Pharmacol， 2020， 11： 598939. doi:10.3389/fphar.2020.598939 doi: 10.3389/fphar.2020.598939
14	TRULSSON F， AKIMOV V， ROBU M， et al. Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates ［J］. Nat Commun， 2022， 13（1）： 2736. doi:10.1038/s41467-022-30376-7 doi: 10.1038/s41467-022-30376-7
15	TOMA-FUKAI S， SHIMIZU T. Structural Diversity of Ubiquitin E3 Ligase ［J］. Molecules， 2021， 26（21）：6682. doi:10.3390/molecules26216682 doi: 10.3390/molecules26216682
16	DIKIC I， SCHULMAN B A. An expanded lexicon for the ubiquitin code ［J］. Nat Rev Mol Cell Biol， 2023， 24（4）： 273-287. doi:10.1038/s41580-022-00543-1 doi: 10.1038/s41580-022-00543-1
17	CRUZ WALMA D A， CHEN Z， BULLOCK A N， et al. Ubiquitin ligases： guardians of mammalian development ［J］. Nat Rev Mol Cell Biol， 2022， 23（5）： 350-367. doi:10.1038/s41580-021-00448-5 doi: 10.1038/s41580-021-00448-5
18	DANG F， NIE L， WEI W. Ubiquitin signaling in cell cycle control and tumorigenesis ［J］. Cell Death Differ， 2021， 28（2）： 427-438. doi:10.1038/s41418-020-00648-0 doi: 10.1038/s41418-020-00648-0
19	LIN J， HOU Y， HUANG S， et al. Exportin-T promotes tumor proliferation and invasion in hepatocellular carcinoma ［J］. Mol Carcinog， 2019， 58（2）： 293-304. doi:10.1002/mc.22928 doi: 10.1002/mc.22928
20	PAN L J， CHEN J L， WU Z X， et al. Exportin-T： A Novel Prognostic Predictor and Potential Therapeutic Target for Neuroblastoma ［J］. Technol Cancer Res Treat， 2021， 20： 15330338211039132. doi:10.1177/15330338211039132 doi: 10.1177/15330338211039132
21	KOKONTIS J M， LIN H P， JIANG S S， et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2， CyclinA， and Skp2 ［J］. PloS One， 2014， 9（10）： e109170. doi:10.1371/journal.pone.0111731 doi: 10.1371/journal.pone.0111731
22	SEXTON R E， HALLAK M N AL， DIAB M， et al. Gastric cancer： a comprehensive review of current and future treatment strategies ［J］. Cancer Metastasis Rev， 2020， 39（4）： 1179-1203. doi:10.1007/s10555-020-09925-3 doi: 10.1007/s10555-020-09925-3
23	XIA J Y， AADAM A A. Advances in screening and detection of gastric cancer ［J］. J Surg Oncol， 2022， 125（7）： 1104-1109. doi:10.1002/jso.26844 doi: 10.1002/jso.26844
24	AJANI J A， D'AMICO T A， BENTREM D J， et al. Gastric Cancer， Version 2.2022， NCCN Clinical Practice Guidelines in Oncology ［J］. J Natl Compr Canc Netw， 2022， 20（2）： 167-192.
25	李相辉，侯艳红，吴凯，等. TXNDC5 siRNA靶向纳米微粒对胃癌模型动物抑瘤作用的实验研究［J］. 实用医学杂志， 2023，39（13）：1634-1640. doi:10.3969/j.issn.1006-5725.2023.13.007 doi: 10.3969/j.issn.1006-5725.2023.13.007
26	CAI Z， MOTEN A， PENG D， et al. The Skp2 Pathway： A Critical Target for Cancer Therapy ［J］. Semin Cancer Biol， 2020， 67（Pt 2）： 16-33. doi:10.1016/j.semcancer.2020.01.013 doi: 10.1016/j.semcancer.2020.01.013

[1]	Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237.
[2]	Jianliang YAN,Zeyu XIE,Rongrong JING,Ming. CUI. Research on establishing gastric cancer lymph node metastasis prediction model based on machine learning and routine laboratory indicators [J]. The Journal of Practical Medicine, 2024, 40(6): 844-849.
[3]	Shu CHEN,Jinglei ZHANG,Kang RONG,Nan ZHANG,Weiyi SUN. Research progress of exosomes in distant metastasis and drug resistance of gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(6): 870-876.
[4]	Li XU,Shanshan HU,Haiming. ZHAO. LncRNA GNAS⁃AS1 participates in the proliferation and migration of gastric cancer cells by regulating the miR⁃449a/Notch1 axis [J]. The Journal of Practical Medicine, 2024, 40(4): 483-489.
[5]	Jian ZHAO,Songjie LIU,Guanchao ZHANG,Yuhou SHEN,Fengchen LI,Bing XU. Expression of CENPF and miR⁃1⁃3p in the serum of patients with advanced gastric cancer and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(3): 365-370.
[6]	Jun XU,Xiaoli WANG,Jingyi NI,Didi. ZHANG. Clinical efficacy and safety of disitamab vedotin in the treatment of advanced gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(20): 2913-2917.
[7]	Chunyan NIU,Xiaoping WANG,Xiangyang ZHAO,Jiankang HUANG,Yue CHEN,Yongqiang SHI,Yongqiang SONG,Hui WANG,Xinguo WU,Yongdan BU,Jijin LI,Tao TAO,Jinhua WU,Changlin XUE,Fuyu ZHANG,Jinming YANG,Chunrong HAN,Juan YUAN,Yinling WU,Hongbing XIONG,Peng XIAO. A multicenter population investigation on precancerous lesions of gastric cancer in Lishui District， Nanjing [J]. The Journal of Practical Medicine, 2024, 40(20): 2929-2934.
[8]	Bei PEI,Yi ZHANG,Qin SUN,Yueping JIN,Xuejun. LI. Study of the association between the chemokine CXCL5 and the onset of chronic atrophic gastritis and gastric precancerous lesions [J]. The Journal of Practical Medicine, 2024, 40(15): 2098-2104.
[9]	Wei WANG,Xinxin ZHANG,Guanghui WANG,Jie ZHANG,Anran CHEN,Jianguang. JIA. TMSB10 promotes gastric cancer proliferation and glycolysis based on activation of AMPK/mTOR signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(11): 1519-1525.
[10]	Wushuang XIAO,Linjie HONG,Zhen YU,Ping YANG,Jieming ZHANG,Siyang PENG,Xiangyang WEI,Yidong CHEN,Side LIU,Jide. WANG. Expression of S100A7A in gastric cancer and its effect on proliferation and metastasis [J]. The Journal of Practical Medicine, 2024, 40(10): 1344-1350.
[11]	Tian GU,Chunhong LIU,Fei ZHANG,Wei QIAN,Yanqiu ZHU,Mingliang CHU,Jiemin. LIU. The mechanism of emodin inhibiting YAP1 and FOXD1 in gastric cancer AGS cells and its related study [J]. The Journal of Practical Medicine, 2024, 40(1): 59-64.
[12]	YAN Jianliang, JING Rongrong, XIE Zeyu, CUI Ming.. Applicationprogress of machine learning in mining of gastric cancer biomarker [J]. The Journal of Practical Medicine, 2023, 39(6): 783-787.
[13]	Xinyuan LU,Yanlu FENG,Jie LI,Siyi XU,Chengyun LI,Tong LIU,Xinhua WANG,Geyu LIANG. Association of genetic variants of m6A binding protein with the risk of gastric cancer [J]. The Journal of Practical Medicine, 2023, 39(21): 2834-2842.
[14]	LI Xianghui, HOU Yanhong, WU Kai, YANG Mi, ZHANG Lin. . Antitumor effect of TXNDC5 siRNA targeted nanoparticles on animal model of gastric cancer：An experi⁃ mental study [J]. The Journal of Practical Medicine, 2023, 39(13): 1634-1640.
[15]	DUAN Ruixue, YANG Bin, XIA Tianhong, YAN Long, LIANG Xiaoqin, LIU Hongbin. . Expression and diagnostic value of plasma exosome PD ⁃L1 in gastric cancer [J]. The Journal of Practical Medicine, 2023, 39(13): 1698-1703.

Role and mechanism of XPOT inhibition by atractylenolide I in gastric cancer cells

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 26

Related Articles 15

Recommended Articles

Metrics

Comments